Skip to main content

Peer Review reports

From: Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study

Original Submission
19 Jun 2015 Submitted Original manuscript
Author responded Author comments
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
7 Dec 2015 Editorially accepted
8 Jan 2016 Article published 10.1186/s12890-015-0156-2

You can find further information about peer review here.

Back to article page